ROIV
Roivant Sciences Ltd. NASDAQ Listed Dec 8, 2020$31.43
+0.74%
vs $31.20
Mkt Cap $22.8B
52w Low $10.74
95.5% of range
52w High $32.41
50d MA $29.13
200d MA $23.56
P/E (TTM)
-131.0x
EV/EBITDA
—
P/B
4.4x
Debt/Equity
0.0x
ROE
-14.2%
P/FCF
-27.0x
RSI (14)
58.70
ATR (14)
$0.93
Beta
1.21
50d MA
$29.13
200d MA
$23.56
Avg Volume
6.2M
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
11-12 St. James's Square · London SW1Y 4LB · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | BMO | -0.29 | -0.28 | +2.2% | 28.21 | +4.9% | +14.9% | -4.7% | -3.0% | -1.0% | -0.3% | — |
| Feb 6, 2026 | BMO | -0.30 | -0.24 | +19.9% | 25.82 | +2.1% | +7.2% | -1.2% | -2.0% | -0.2% | -1.1% | — |
| Nov 10, 2025 | BMO | -0.32 | -0.28 | +12.4% | 21.17 | +0.5% | -1.3% | +2.0% | -3.6% | -1.3% | +1.3% | — |
| Aug 11, 2025 | BMO | -0.25 | -0.18 | +27.9% | 11.17 | +1.2% | +3.6% | +3.4% | -1.8% | +0.9% | -0.3% | — |
| May 29, 2025 | BMO | -0.26 | -0.22 | +16.5% | 11.30 | +0.0% | -2.7% | +1.6% | +0.7% | -0.4% | -0.1% | — |
| Feb 10, 2025 | BMO | -0.24 | -0.13 | +45.8% | 10.79 | -0.3% | -2.8% | -0.5% | +0.1% | +1.1% | +1.1% | — |
| Nov 12, 2024 | BMO | -0.25 | -0.29 | -17.4% | 11.64 | +1.6% | +2.7% | -2.6% | -3.8% | -0.4% | +1.3% | — |
| Aug 8, 2024 | BMO | -0.24 | -0.18 | +26.0% | 10.85 | +0.0% | +2.5% | +0.5% | +1.6% | +0.6% | -1.0% | — |
| May 30, 2024 | BMO | -0.26 | -0.23 | +13.0% | 10.39 | +1.1% | -0.3% | +4.8% | -1.2% | +1.4% | -2.4% | — |
| Feb 13, 2024 | BMO | -0.27 | -0.21 | +22.2% | 10.80 | +0.0% | +4.8% | +1.1% | +1.2% | -0.4% | +0.0% | — |
| Nov 13, 2023 | BMO | -0.28 | -0.26 | +7.1% | 9.05 | +3.9% | +2.8% | -2.5% | -0.6% | -0.6% | -1.9% | — |
| Aug 14, 2023 | BMO | -0.26 | -0.38 | -46.2% | 11.71 | +0.1% | -6.3% | -1.5% | -3.1% | +3.8% | +0.8% | — |
| Jun 28, 2023 | AMC | -0.41 | -0.20 | +51.2% | 10.07 | +0.8% | -1.7% | +1.8% | -3.2% | +8.9% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.39 | $29.65 | +0.9% | -0.7% | +2.2% | -2.5% | +0.7% | -0.5% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.85 | $28.44 | +2.1% | +6.0% | +0.7% | -3.2% | +2.6% | +0.6% |
| Feb 10 | Citigroup | Maintains | Buy → Buy | — | $27.67 | $27.50 | -0.6% | -1.2% | -2.0% | -0.2% | -1.1% | +2.4% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.67 | $27.50 | -0.6% | -1.2% | -2.0% | -0.2% | -1.1% | +2.4% |
| Feb 9 | Guggenheim | Maintains | Buy → Buy | — | $25.82 | $26.35 | +2.1% | +7.2% | -1.2% | -2.0% | -0.2% | -1.1% |
| Dec 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $22.10 | $22.20 | +0.5% | -0.9% | +4.7% | -1.0% | -4.0% | +2.8% |
| Dec 15 | Goldman Sachs | Maintains | Buy → Buy | — | $22.10 | $22.20 | +0.5% | -0.9% | +4.7% | -1.0% | -4.0% | +2.8% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.34 | $21.77 | +2.0% | +3.6% | -0.9% | +4.7% | -1.0% | -4.0% |
| Nov 11 | Citigroup | Maintains | Buy → Buy | — | $21.17 | $21.27 | +0.5% | -1.3% | +2.0% | -3.6% | -1.3% | +1.3% |
| Oct 29 | Citigroup | Maintains | Buy → Buy | — | $18.41 | $18.36 | -0.3% | +1.9% | +4.4% | +2.1% | -2.0% | +1.4% |
| Sep 18 | Leerink Partners | Maintains | Outperform → Outperform | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | JP Morgan | Maintains | Overweight → Overweight | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | Jefferies | Maintains | Buy → Buy | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | BofA Securities | Maintains | Neutral → Neutral | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | Guggenheim | Maintains | Buy → Buy | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Sep 18 | Goldman Sachs | Maintains | Buy → Buy | — | $15.28 | $15.04 | -1.6% | -1.2% | -0.3% | -0.7% | -1.3% | -0.3% |
| Jun 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.11 | $11.15 | +0.4% | +3.0% | +0.1% | +0.4% | +0.3% | -1.2% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.76 | $10.75 | -0.1% | -1.3% | +6.4% | -2.7% | +1.6% | +0.7% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.15 | $10.15 | +0.0% | -1.1% | +3.8% | +3.1% | +2.4% | +0.1% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.79 | $10.76 | -0.3% | -2.8% | -0.5% | +0.1% | +1.1% | +1.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.64 | $11.83 | +1.6% | +2.7% | -2.6% | -3.8% | -0.4% | +1.3% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.00 | $12.03 | +0.2% | -0.7% | +0.4% | -0.6% | -1.8% | +0.7% |
| Sep 11 | BofA Securities | Maintains | Neutral → Neutral | — | $12.19 | $12.27 | +0.7% | +1.6% | -2.1% | -1.5% | +0.8% | +0.1% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.19 | $12.27 | +0.7% | +1.6% | -2.1% | -1.5% | +0.8% | +0.1% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.19 | $11.20 | +0.1% | +2.7% | -0.1% | +2.7% | -0.9% | +1.7% |
| Jul 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.83 | $10.87 | +0.4% | +3.9% | -0.1% | +1.0% | +1.3% | +1.0% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.39 | $10.50 | +1.1% | -0.3% | +4.8% | -1.2% | +1.4% | -2.4% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.46 | $10.52 | +0.6% | +1.3% | +3.2% | -0.4% | -0.2% | +1.4% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.92 | $10.92 | +0.0% | +5.4% | +0.0% | +2.0% | -0.9% | -1.9% |
| Apr 3 | Goldman Sachs | Maintains | Buy → Buy | — | $10.92 | $10.92 | +0.0% | +5.4% | +0.0% | +2.0% | -0.9% | -1.9% |
| Apr 3 | Deutsche Bank | Maintains | Buy → Buy | — | $10.92 | $10.92 | +0.0% | +5.4% | +0.0% | +2.0% | -0.9% | -1.9% |
| Mar 25 | Truist | Maintains | Buy → Buy | — | $10.15 | $10.16 | +0.1% | -2.0% | +1.3% | +7.5% | -2.8% | -1.0% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.80 | $10.80 | +0.0% | +4.8% | +1.1% | +1.2% | -0.4% | +0.0% |
| Jan 2 | BofA Securities | Maintains | Neutral → Neutral | — | $11.23 | $11.22 | -0.1% | +1.1% | -4.3% | -0.4% | +4.2% | +1.5% |
| Nov 15 | Guggenheim | Maintains | Buy → Buy | — | $9.30 | $9.25 | -0.5% | -2.5% | -0.6% | -0.6% | -1.9% | -1.8% |
| Nov 14 | JP Morgan | Maintains | Overweight → Overweight | — | $9.05 | $9.40 | +3.9% | +2.8% | -2.5% | -0.6% | -0.6% | -1.9% |
| Sep 27 | Goldman Sachs | Maintains | Buy → Buy | — | $12.41 | $12.77 | +2.9% | +6.3% | -4.9% | -6.9% | -10.0% | -0.9% |
| Sep 26 | Truist | Maintains | Buy → Buy | — | $10.21 | $11.80 | +15.6% | +21.5% | +6.3% | -4.9% | -6.9% | -10.0% |
| Sep 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.29 | $11.17 | -1.1% | -1.5% | -2.9% | -4.4% | -1.1% | +1.1% |
| Sep 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.68 | $11.63 | -0.4% | +0.6% | +0.3% | -0.8% | +7.7% | -8.7% |
| Aug 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.58 | $11.58 | +0.0% | -0.1% | +1.0% | +0.6% | +0.3% | -0.8% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.96 | $10.99 | +0.3% | +1.7% | +5.0% | -5.1% | +0.3% | +1.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.71 | $11.72 | +0.1% | -6.3% | -1.5% | -3.1% | +3.8% | +0.8% |
| Jul 14 | Truist | Maintains | Buy → Buy | — | $11.60 | $11.99 | +3.4% | +0.6% | +1.1% | +0.1% | -2.3% | -3.6% |
| Jun 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.07 | $10.15 | +0.8% | -1.7% | +1.8% | -3.2% | +8.9% | +0.2% |
| Jun 23 | Truist | Maintains | Buy → Buy | — | $9.97 | $10.00 | +0.3% | -1.7% | -6.3% | -1.4% | +11.3% | -1.7% |
| Jun 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.97 | $10.00 | +0.3% | -1.7% | -6.3% | -1.4% | +11.3% | -1.7% |
| Jun 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.65 | $9.52 | -1.3% | +1.5% | -2.7% | +4.6% | -1.7% | -6.3% |
| Jun 9 | JP Morgan | Maintains | Overweight → Overweight | — | $9.58 | $9.63 | +0.5% | +4.7% | -6.1% | +3.8% | -0.7% | +2.2% |
No insider trades available.
8-K · 2.02
!! High
Roivant Sciences Ltd. -- 8-K 2.02: Earnings Results
Roivant Sciences reported quarterly earnings results via press release, with detailed financial performance and operational updates disclosed in the attached exhibit for investor review.
May 20
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Immunovant's batoclimab Phase 3 thyroid eye disease data and brepocitinib advancement could drive near-term clinical catalysts, but investors should await detailed results to assess commercial viability and likelihood of regulatory approval.
Apr 2
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Settlement with Moderna likely ends costly litigation risk for these biotech companies, potentially freeing resources for R&D and improving profit visibility going forward.
Mar 23
8-K · 8.01
!! High
Roivant Sciences Ltd. Common Shares -- 8-K 8.01: Material Event / Announcement
Roivant Sciences doubled its share repurchase authorization to $1 billion, signaling management confidence in the stock's valuation and commitment to returning capital to shareholders.
Mar 3
8-K · 7.01
! Medium
Roivant Sciences Ltd. Common Shares -- 8-K 7.01: Regulation FD Disclosure
Roivant Sciences' FDA acceptance of brepocitinib's NDA with Priority Review for dermatomyositis treatment accelerates the potential approval timeline for this subsidiary asset.
Mar 3
8-K
Roivant Sciences Ltd. Common Shares -- 8-K Filing
Roivant Sciences' brepocitinib showed positive Phase 2 results for cutaneous sarcoidosis, significantly outperforming placebo with a 21.6-point efficacy advantage, supporting potential regulatory approval and commercial viability.
Feb 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 116,719,106 | $2.5B | Added | Dec 2025 |
| 2 | Fmr Llc | 77,981,253 | $2.2B | Added | Mar 2026 |
| 3 | Ubs Group Ag | 22,619,472 | $627M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 20,680,572 | $573M | New | Mar 2026 |
| 5 | Vanguard Portfolio Management Llc | 19,838,698 | $550M | New | Mar 2026 |
| 6 | Farallon Capital Management Llc | 9,675,000 | $268M | New | Mar 2026 |
| 7 | Assenagon Asset Management S.a. | 7,076,488 | $196M | Added | Mar 2026 |
| 8 | Viking Global Investors | 6,652,448 | $184M | Added | Mar 2026 |
| 9 | Invesco Ltd. | 6,439,145 | $178M | Added | Mar 2026 |
| 10 | Aqr Capital Management Llc | 5,946,858 | $162M | Added | Mar 2026 |
| 11 | Northern Trust Corp | 3,520,452 | $98M | Added | Mar 2026 |
| 12 | Qube Research & Technologies Ltd | 3,450,904 | $96M | Added | Mar 2026 |
| 13 | Adar1 Capital Management, Llc | 3,285,906 | $91M | New | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 3,163,821 | $88M | Added | Mar 2026 |
| 15 | Janus Henderson Group Plc | 3,095,448 | $86M | New | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 2,735,824 | $76M | Reduced | Mar 2026 |
| 17 | Sb Investment Advisers (Uk) Ltd | 2,671,732 | $74M | New | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 2,516,353 | $70M | Added | Mar 2026 |
| 19 | Citadel Advisors Llc | 2,515,998 | $70M | Added | Mar 2026 |
| 20 | Marshall Wace, Llp | 2,246,943 | $62M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$22.80B
Enterprise Value
$17.91B
P/E (TTM)
-130.96x
Forward P/E
—
PEG Ratio
0.41x
P/B
4.40x
P/S
784.75x
P/FCF
-27.01x
EV/EBITDA
—
Shares Out
725.4M
Financials (TTM)
Revenue
$29.1M
Net Income
-$172.0M
EBITDA
-$1.10B
Free Cash Flow
-$844.0M
Op Cash Flow
-$839.5M
EPS Basic
$-0.24
EPS Diluted
$-0.24
EPS Forward
$-1.18
Gross Margin
96.9%
Op Margin
-3453.3%
Net Margin
-592.0%
Balance Sheet
Total Assets
$5.44B
Total Liab.
$249.7M
Total Equity
$5.19B
Cash
$4.89B
LT Debt
$0
Book Value/Sh
$7.15
Debt/Equity
0.02x
Current Ratio
33.47
Quick Ratio
33.47
Returns & Growth
ROE
-14.2%
ROA
-11.6%
ROIC
-18.9%
Rev Growth YoY
-11.2%
EPS Growth YoY
-104.3%
Price Returns
2W
+1.7%
1M
+5.1%
3M
+3.6%
6M
+44.1%
12M
+172.9%
Technicals
52W High
$32.41
52W Low
$10.74
50d MA
$29.13
200d MA
$23.56
RSI (14)
58.70
ATR (14)
$0.93
Beta
1.21
Avg Volume
6.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$33.20
High
$40.00
Low
$30.00
Median
$32.00
Data updated apr 26, 2026 11:20pm
· Source: financialmodelingprep.com